NPPB and heart failure: It was recently approved by the FDA and advocated for by the ACCF/AHA guidelines for risk stratification and prognostication in patients with heart failure [13] due to its performance in predicting risk of sudden death, CV events, all-cause mortality and providing better discrimination of 2 year CV risk than NT-ProBNP and cTnT [14–17].